Table 4.
Areas under the receiver operating curve for assessing the performance of gene expression levels and biomarkers and their optimal operating points to rule out organ dysfunction.
| AUROC | p-Value | OOP | Sensitivity | Specificity | |
|---|---|---|---|---|---|
| HLA-DRA | * 0.719 (0.616-0.822) | * <0.001 | 1204 copies/ng RNA | 0.635 | 0.738 |
| ICOS | * 0.619 (0.505-0.733) | * 0.048 | 13 copies/ng RNA | 0.577 | 0.714 |
| CD40LG | * 0.671 (0.562-0.780) | * 0.005 | 29 copies/ng RNA | 0.538 | 0.833 |
| CD3E | * 0.654 (0.542-0.766) | * 0.010 | 234 copies/ng RNA | 0.635 | 0.667 |
| CD28 | * 0.657 (0.546-0.768) | * 0.009 | 38 copies/ng RNA | 0.538 | 0.833 |
| ProET1 | 0.775 (0.663-0.886) | * <0.001 | 87 pmol/L | 0.676 | 0.795 |
| ProADM | 0.756 (0.646-0.865) | * <0.001 | 0.9 nmol/L | 0.618 | 0.744 |
AUROC: area under the receiver operating curve; OOP: optimal operating point; ProET1: proendothelin-1; ProADM: proadrenomedullin; HLA-DRA: histocompatibility complex class II DR alpha; ICOS: Inducible T-cell costimulator; CD40LG: CD40 ligand * p < 0.05.